Human IgG2 antibodies display disulfide-mediated structural isoforms. - Wikidata - awgldk - TriplyDB

Human IgG2 antibodies display disulfide-mediated structural isoforms.

Human IgG2 antibodies display disulfide-mediated structural isoforms.

http://www.wikidata.org/entity/Q35676381

about

Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats Posttranslational Modifications and the Immunogenicity of Biotherapeutics Influence of immunoglobulin isotype on therapeutic antibody function Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function Stability engineering of the human antibody repertoire In vitro and in vivo modifications of recombinant and human IgG antibodies The effect of tensile stress on the conformational free energy landscape of disulfide bonds Enhancing Protein Disulfide Bond Cleavage by UV Excitation and Electron Capture Dissociation for Top-Down Mass Spectrometry Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice Production of IgG antibodies to pneumococcal polysaccharides is associated with expansion of ICOS+ circulating memory T follicular-helper cells which is impaired by HIV infection.Antiviral Functions of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific IgG Antibodies: Effects of Antiretroviral Therapy and Implications for Therapeutic HIV-1 Vaccine Design.Disulphide bond reduction of a therapeutic monoclonal antibody during cell culture manufacturing operations Removal of a C-terminal serine residue proximal to the inter-chain disulfide bond of a human IgG1 lambda light chain mediates enhanced antibody stability and antibody dependent cell-mediated cytotoxicity On the perplexingly low rate of transport of IgG2 across the human placenta.IgG subclasses and allotypes: from structure to effector functions.Structural and functional characterization of the trifunctional antibody catumaxomab Protected hinge in the immunoglobulin G2-A2 disulfide isoform Three-dimensional structure of the human myeloma IgG2.Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.Advanced mass spectrometry workflows for analyzing disulfide bonds in biologics.Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell-Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification.A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis.Alleviating nonlinear behavior of disulfide isoforms in the reversed-phase liquid chromatography of IgG2.PDADMAC flocculation of Chinese hamster ovary cells: enabling a centrifuge-less harvest process for monoclonal antibodies.Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies.Complementary MS methods assist conformational characterization of antibodies with altered S-S bonding networks.Effects of subclass change on the structural stability of chimeric, humanized, and human antibodies under thermal stress.Developability studies before initiation of process development: improving manufacturability of monoclonal antibodies.Stability of IgG isotypes in serum.Cysteine tagging for MS-based proteomics.Post-translational structural modifications of immunoglobulin G and their effect on biological activity.Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates The multiple facets of FcRn in immunity.Direct observation of disulfide isomerization in a single protein.Impact of cell culture on recombinant monoclonal antibody product heterogeneity.Assessment of disulfide and hinge modifications in monoclonal antibodies Human Fc receptor-like 5 binds intact IgG via mechanisms distinct from those of Fc receptors.Comparative study of the three different fluorophore antibody conjugation strategies.The in vitro resistance of IgG2 to proteolytic attack concurs with a comparative paucity of autoantibodies against peptide analogs of the IgG2 hinge.Relative stabilities of IgG1 and IgG4 Fab domains: influence of the light-heavy interchain disulfide bond architecture

P2860

Q24619854-AA448444-A407-4A71-B71C-4BA6627CAD72 Q26748614-2C7E8C46-1FE4-4A25-9D11-436AEA40B0E9 Q26772080-BD8C2A08-6315-44D3-A54F-3EFD6D227512 Q26823047-50434D70-65E8-40E6-9C42-6FFF1E933E68 Q26859495-6311D9F5-6588-4F55-A01B-572ED85D6125 Q26859713-7CE65F9A-DDAC-480B-BD75-FCDE0B5AEE21 Q28543570-FE692D3C-618B-423B-8EC1-BFF070F68F67 Q30382274-CF1E4F43-CBCA-40A9-BEFB-40C1D46E1B5B Q33402880-21F40125-691D-4842-B5DA-E28C8E001A39 Q33626626-CB46B0B4-5C9A-4DE1-9B7D-461AECAD05F1 Q33867299-37654B81-78E1-4243-9FC0-91BF4DEC5593 Q34176426-44F728CE-1692-41AA-A867-01DCA209F472 Q34212771-2034C88D-70D2-4FBB-9AE9-EBD53B58A20D Q34253508-2C159723-493A-4F25-B988-8E5449AD3134 Q34368678-306DA1E9-269B-4185-AB34-047AA3674E02 Q34619043-480ED0D6-1BE0-41D5-AEC4-5FD5ABF40687 Q34621325-4DB6A366-113E-4B0C-B26D-F1AF4421CF15 Q34769388-C325CA36-3279-4406-B7E0-76649C30C2FC Q34978570-BE1D7547-1BB2-4077-A2BC-706EF0ACE8DF Q35568366-111A3C48-92F2-4864-B58D-927CD36BA42A Q35823060-8CA09022-8264-47CB-8F40-8070D6DB15BE Q36059455-1D4279AA-3E02-45DE-ABF8-9A99951026BF Q36161091-F472714D-2B39-4876-AB4F-A624C7BA8DFF Q36212851-B27EE423-FC31-4EF4-97BE-F2FC4D4FFB39 Q36402682-B1E50DD2-9DB3-4897-949D-6D2A24B4B7C4 Q36836949-E0AE9249-CA68-4A61-A85E-D7333196B43A Q37318764-7D196B89-1F48-4A1A-910C-FD76FAD65C0C Q37364361-A5D4DDB8-03E6-406F-91AF-4C5F68D9058B Q37734089-3F7C03DC-0BBA-4EE5-BCAB-BA81D96A5C98 Q37866224-83B8EB40-4393-48A6-AC0A-89A42CDD3F16 Q38246996-A16B2FA9-6AD4-4D3A-ABFA-38DCE24DD55C Q38262066-040E4F1D-6F59-4FDC-9955-EA2FD47CC588 Q38615385-D4F71F16-A2EF-4F7E-9C8F-DE2C2D990EF4 Q38892188-A5AC8D79-DE43-4BC5-8537-14F6C83D104A Q38907094-DC365420-9007-44F4-8C05-6E1409C0A4E0 Q39041113-3A8D5533-7603-4E15-A6B9-15780F4160B4 Q39160831-6CD14ABA-3BBE-4CF5-B707-FC6D84FC6C52 Q39314271-3726A043-7E4D-45EE-9ACE-AD6A26EE3DE3 Q39917896-D153BD85-78E1-47DE-8C45-8148E729C860 Q39970297-EFA7C016-041E-45A2-9ECC-5D29AD7479FC

P2860

Human IgG2 antibodies display disulfide-mediated structural isoforms.

http://www.wikidata.org/entity/Q35676381

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Human IgG2 antibodies display disulfide-mediated structural isoforms.

@ast

Human IgG2 antibodies display disulfide-mediated structural isoforms.

@en

type

label

Human IgG2 antibodies display disulfide-mediated structural isoforms.

@ast

Human IgG2 antibodies display disulfide-mediated structural isoforms.

@en

prefLabel

Human IgG2 antibodies display disulfide-mediated structural isoforms.

@ast

Human IgG2 antibodies display disulfide-mediated structural isoforms.

@en

P1433

Q35676381-A11BC30C-9932-4180-B922-5563DAB87FB7

P1476

Q35676381-D29A02EA-3C42-40CE-9C6C-9D1B08D04272

P2093

Q35676381-095B14A9-B760-48D1-A2EC-A84ABA290BEF

Q35676381-3DE0B6F5-E06C-4807-815F-52C7A6A849A7

Q35676381-492897A5-4BF3-4D24-8AEE-2FF55F9E201B

Q35676381-4EA179E3-D5F0-40E9-BF42-931308EAD988

Q35676381-66A1756D-CC16-4FD6-A790-BE69722639B2

Q35676381-7AE56376-7B11-428C-9D80-CAC530021741

Q35676381-82D9D8A3-2213-4C15-920D-157DD6D0BB09

Q35676381-8A08B006-2A55-4349-BA03-5D3C990B60E3

Q35676381-8AD681FD-C2B9-4027-A38F-1771A2A4807D

Q35676381-E11E9595-7E4B-4217-B0E3-85EA89050880

P2860

Q35676381-077ECDC0-C8F9-4B42-B2FB-E5E835BE2A74

Q35676381-0C22D3F2-3376-4FB4-AD37-CB754D74194D

Q35676381-0C9A4ABC-115C-48D9-9DC6-00DC06549A25

Q35676381-1327E0EC-4C10-4356-889C-D22E6DAF0886

Q35676381-197C95BD-3915-4BD8-9676-EF2D0E00CE46

Q35676381-1BA30F9C-8B10-4D05-A8AB-12F5D645D67F

Q35676381-1F345806-3AB0-4441-AE0D-AC79545AE09C

Q35676381-2AF4E0C0-4FC1-456E-9C05-D26C5A8F3084

Q35676381-350CBC22-E821-458A-80A5-45E33E810A43

Q35676381-361B7CC3-3E08-43A0-BACA-E6A382BCD15F

P304

Q35676381-364A7574-B2A5-402B-961C-FCF9E9F5ADF0

P31

Q35676381-919C41B3-A5AF-48D5-B35C-2A3F72A28569

P356

Q35676381-2CDE05A0-16BF-482E-AE71-657ED22D05EC

P407

Q35676381-94CBAE73-6FE1-4508-9AD2-364CDBDAD630

P433

Q35676381-D429BCC3-AE7D-48A4-84BB-1A55621553D0

P478

Q35676381-2F31778E-78F0-4018-9536-4C60B964FDAA

P577

Q35676381-14690D99-F2F0-47D0-B6FA-CB0011B956A3

P698

Q35676381-9F90BF01-0C5E-4685-BAE6-50D6184B565B

P921

Q35676381-8BA22B78-D8F7-46C3-9D23-08BB66A6526B

P932

Q35676381-A0325BCC-4695-4B17-AC14-F2F04CF864F5

P356

P1433

Journal of Biological Chemistry

P1476

Human IgG2 antibodies display disulfide-mediated structural isoforms.

@en

P2093

Alain Balland

http://www.w3.org/2001/XMLSchema#string

Amy Guo

http://www.w3.org/2001/XMLSchema#string

Drew N Kelner

http://www.w3.org/2001/XMLSchema#string

Gregory C Flynn

http://www.w3.org/2001/XMLSchema#string

Jette Wypych

http://www.w3.org/2001/XMLSchema#string

Margaret Speed Ricci

http://www.w3.org/2001/XMLSchema#string

Martin J Allen

http://www.w3.org/2001/XMLSchema#string

Ming Li

http://www.w3.org/2001/XMLSchema#string

Pavel V Bondarenko

http://www.w3.org/2001/XMLSchema#string

Szilan Fodor

http://www.w3.org/2001/XMLSchema#string

P2860

Disulphide bridges of the heavy chain of human immunoglobulin G2

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design

Downstream processing of monoclonal antibodies--application of platform approaches

Conformational analysis of the eight-membered ring of the oxidized cysteinyl-cysteine unit implicated in nicotinic acetylcholine receptor ligand recognition.

The covalent structure of an entire gammaG immunoglobulin molecule.

Structural studies of immunoglobulin G.

IgG4 breaking the rules.

The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region.

The structural basis for the functional versatility of immunoglobulin G1.

Modulation of the effector functions of a human IgG1 through engineering of its hinge region.

P304

16194-16205

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M709987200

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

283

http://www.w3.org/2001/XMLSchema#string

P577

2008-03-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18339624

http://www.w3.org/2001/XMLSchema#string

P921

P932

3259661

http://www.w3.org/2001/XMLSchema#string